R
Richard J. Colonno
Researcher at Bristol-Myers Squibb
Publications - 146
Citations - 14924
Richard J. Colonno is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Entecavir & Hepatitis B virus. The author has an hindex of 57, co-authored 141 publications receiving 14236 citations. Previous affiliations of Richard J. Colonno include Hoffmann-La Roche.
Papers
More filters
Journal ArticleDOI
Identification of N-Hydroxamic Acid and N-Hydroxyimide Compounds that Inhibit the Influenza Virus Polymerase
Christopher Cianci,Thomas D. Y. Chung,Nicholas A. Meanwell,H. Putz,Moira Hagen,Richard J. Colonno,Mark Krystal +6 more
TL;DR: In an effort to discover antiviral compounds against this target, an in-vitro transcription assay was utilized to screen a proprietary chemical collection and identified two related N-hydroxyimide compounds as specific inhibitors of the cap-scavenging mechanism of influenza virus.
Journal ArticleDOI
Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir.
Makonen Belema,Van N. Nguyen,Carol Bachand,Deon Daniel H,Goodrich Jason,James Clint A,Lavoie Rico,Lopez Omar D,Alain Martel,Jeffrey L. Romine,Ruediger Edward H,Lawrence B. Snyder,Denis R. St. Laurent,Fukang Yang,Juliang Zhu,Henry S. Wong,David R. Langley,Stephen P. Adams,Glenn H. Cantor,Anjaneya Chimalakonda,Aberra Fura,Benjamin M. Johnson,Jay O. Knipe,Dawn D. Parker,Kenneth S. Santone,Robert A. Fridell,Julie A. Lemm,Donald R. O'Boyle,Richard J. Colonno,Min Gao,Nicholas A. Meanwell,Lawrence G. Hamann +31 more
TL;DR: Clinical proof-of-concept for the NS5A replication complex inhibitor class, and regulatory approval to market it with the NS3/4A protease inhibitor asunaprevir for the treatment of HCV genotype-1b infection has recently been sought in Japan.
Journal ArticleDOI
Potent Efficacy of Entecavir (BMS-200475) in a Duck Model of Hepatitis B Virus Replication
TL;DR: Results show that ETV is a highly potent and effective antiviral in the DHBV duck model and both ETV and 3TC were both well tolerated in all treated animals.
Journal ArticleDOI
Characterization of a hemagglutinin-specific inhibitor of influenza A virus.
TL;DR: Experiments further illustrate that the hemagglutinin protein of influenza virus is a viable target for the discovery and development of small molecule inhibitors of virus growth.
Journal ArticleDOI
Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase.
Robert G. Gentles,Min Ding,Bender John A,Bergstrom Carl P,Katharine A. Grant-Young,Piyasena Hewawasam,Thomas W. Hudyma,Scott W. Martin,Andrew Nickel,Alicia Regueiro-Ren,Yong Tu,Zhong Yang,Kap-Sun Yeung,Xiaofan Zheng,Sam T. Chao,Jung-Hui Sun,Brett R. Beno,Daniel M. Camac,Chong-Hwan Chang,Mian Gao,Paul E. Morin,Steven Sheriff,Jeff Tredup,John Wan,Mark R. Witmer,Dianlin Xie,Umesh Hanumegowda,Jay O. Knipe,Kathy Mosure,Kenneth S. Santone,Dawn D. Parker,Xiaoliang Zhuo,Julie A. Lemm,Mengping Liu,Lenore A. Pelosi,Karen Rigat,Voss Stacey A,Yi Wang,Ying-Kai Wang,Richard J. Colonno,Min Gao,Susan B. Roberts,Qi Gao,Alicia Ng,Nicholas A. Meanwell,John F. Kadow +45 more
TL;DR: Structural-activity relationship studies resulted in the optimization of the activity of members of a class of cyclopropyl-fused indolobenzazepine HCV NS5B polymerase inhibitors, and analogues exhibiting improved solubility and membrane permeability were shown to have notably enhanced pharmacokinetic profiles.